Management of Persistent Depression Following Cannabis-Induced Psychosis
Optimize the antidepressant therapy by increasing mirtazapine to 45 mg nightly or switching to a different antidepressant class, while maintaining brexpiprazole 3 mg and tapering off clonazepam and eszopiclone (Lunesta).
Current Medication Assessment
Your patient's regimen requires several adjustments:
Brexpiprazole 3 mg: This is appropriate and should be continued. The dose is within therapeutic range for psychosis management, and brexpiprazole has demonstrated efficacy in patients with schizophrenia spectrum disorders regardless of substance use comorbidity 1. The absence of hallucinations indicates good control of positive symptoms.
Mirtazapine 30 mg: This is a suboptimal dose for major depression. Mirtazapine's antidepressant efficacy typically requires 45 mg daily due to increased noradrenergic activity at higher doses. At 30 mg, you're primarily getting sedation and antihistamine effects without maximal antidepressant benefit.
Eszopiclone (Lunesta) 1 mg + Clonazepam 0.25 mg daily: This combination is problematic. You're using two sedative-hypnotics when mirtazapine at proper dosing should address sleep. The FDA label warns that eszopiclone can cause complex behaviors, amnesia, and worsening depression 2. Benzodiazepines like clonazepam carry dependence risk and can worsen depression long-term.
Recommended Treatment Algorithm
Step 1: Address the Depression (Primary Issue)
Option A - Optimize Current Regimen:
- Increase mirtazapine to 45 mg nightly
- This addresses both depression and sleep without additional sedative-hypnotics
- Monitor for 4-6 weeks for response
Option B - Switch Antidepressant:
- If mirtazapine optimization fails or side effects are problematic, switch to an SSRI (sertraline 50-200 mg or escitalopram 10-20 mg) or SNRI (venlafaxine XR 75-225 mg)
- These have better evidence for depression in psychotic disorders when combined with antipsychotics
Step 2: Taper Unnecessary Sedatives
- Discontinue eszopiclone immediately - it's redundant with mirtazapine and carries risks of behavioral changes and depression worsening 2
- Taper clonazepam over 2-4 weeks - reduce by 0.125 mg every 5-7 days to avoid withdrawal
- Benzodiazepines were appropriate for acute agitation in cannabis-induced psychosis 3, 4 but have no role 4 months out
Step 3: Continue Antipsychotic Maintenance
- Maintain brexpiprazole 3 mg - this is appropriate for preventing psychotic relapse
- Current guidelines recommend continuing the same antipsychotic that achieved symptom control 5
- Brexpiprazole specifically shows efficacy in substance use disorder populations and may reduce cannabis craving if relapse occurs 1
Critical Diagnostic Consideration
At 4 months post-cannabis-induced psychosis, you must reassess the diagnosis. Recent meta-analysis shows that 20% of cannabis-induced psychosis cases convert to schizophrenia spectrum disorder 6. The persistent depression with resolved psychosis suggests:
- Primary depressive episode (most likely given symptom pattern)
- Negative symptoms of emerging schizophrenia (less likely without cognitive/functional decline)
- Bipolar depression (5% conversion rate from cannabis-induced psychosis 6)
Key differentiating features to assess:
- Functional impairment pattern (pervasive vs. episodic)
- Cognitive symptoms (concentration, memory, executive function)
- Anhedonia severity and quality
- Family history of mood vs. psychotic disorders
- Presence of subsyndromal psychotic symptoms
Cannabis Abstinence Monitoring
Verify continued abstinence - even occasional cannabis use significantly increases risk of:
- Conversion to schizophrenia spectrum disorder (20% baseline risk 6)
- Persistent hopelessness and depression (31-35% mediation effect 7)
- Psychotic relapse (HR 4.32 with combined depression and cannabis use 7)
Timeline for Reassessment
- 2 weeks: Assess tolerability of medication changes
- 4-6 weeks: Evaluate antidepressant response (50% symptom reduction is adequate response)
- 12 weeks: If inadequate response, consider switching antidepressant class or augmentation strategies
- 6 months: Reassess need for continued antipsychotic if no psychotic symptoms recur and cannabis abstinence maintained
Common Pitfalls to Avoid
- Don't continue polypharmacy with sedatives - mirtazapine alone should manage sleep
- Don't undertreate the depression - 30 mg mirtazapine is insufficient
- Don't prematurely discontinue brexpiprazole - maintain for at least 12 months post-psychosis per guidelines 8, 5
- Don't assume this is just residual psychosis - the symptom pattern (depression without hallucinations) indicates a mood disorder component requiring specific treatment
The evidence strongly supports addressing the depression as the primary therapeutic target while maintaining antipsychotic prophylaxis and eliminating unnecessary sedative-hypnotics.